1. Home
  2. HSPO vs IMUX Comparison

HSPO vs IMUX Comparison

Compare HSPO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • IMUX
  • Stock Information
  • Founded
  • HSPO 2014
  • IMUX 2016
  • Country
  • HSPO United States
  • IMUX United States
  • Employees
  • HSPO N/A
  • IMUX N/A
  • Industry
  • HSPO Blank Checks
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • IMUX Health Care
  • Exchange
  • HSPO Nasdaq
  • IMUX Nasdaq
  • Market Cap
  • HSPO 91.5M
  • IMUX 86.3M
  • IPO Year
  • HSPO 2022
  • IMUX N/A
  • Fundamental
  • Price
  • HSPO $11.74
  • IMUX $0.98
  • Analyst Decision
  • HSPO
  • IMUX Strong Buy
  • Analyst Count
  • HSPO 0
  • IMUX 6
  • Target Price
  • HSPO N/A
  • IMUX $12.67
  • AVG Volume (30 Days)
  • HSPO 3.2K
  • IMUX 1.0M
  • Earning Date
  • HSPO 01-01-0001
  • IMUX 02-20-2025
  • Dividend Yield
  • HSPO N/A
  • IMUX N/A
  • EPS Growth
  • HSPO 2.63
  • IMUX N/A
  • EPS
  • HSPO 0.28
  • IMUX N/A
  • Revenue
  • HSPO N/A
  • IMUX N/A
  • Revenue This Year
  • HSPO N/A
  • IMUX N/A
  • Revenue Next Year
  • HSPO N/A
  • IMUX N/A
  • P/E Ratio
  • HSPO $41.64
  • IMUX N/A
  • Revenue Growth
  • HSPO N/A
  • IMUX N/A
  • 52 Week Low
  • HSPO $10.77
  • IMUX $0.92
  • 52 Week High
  • HSPO $12.41
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 55.44
  • IMUX 44.34
  • Support Level
  • HSPO $11.68
  • IMUX $0.94
  • Resistance Level
  • HSPO $12.10
  • IMUX $1.02
  • Average True Range (ATR)
  • HSPO 0.14
  • IMUX 0.06
  • MACD
  • HSPO -0.00
  • IMUX 0.00
  • Stochastic Oscillator
  • HSPO 32.32
  • IMUX 44.96

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: